J&J Says It Sues US to Challenge Drug-Pricing Provisions

Johnson & Johnson said it sued the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services over the drug-pricing provisions of the Inflation Reduction Act.

• The pricing provisions would “upend the current self-sustaining cycle of pharmaceutical innovation,” J&J said in statement on its website
• “The IRA’s pricing provisions will constrain medical innovation, limit patient access and choice, and negatively impact the overall quality of patient care,” J&J said

To view the source of this information, click here

To contact the reporter on this story:
Greg Chang in San Francisco at gchang1@bloomberg.net

To ...